
浏览全部资源
扫码关注微信
1.贵州医科大学公共卫生与健康学院,环境污染与疾病监控教育部重点实验室,贵阳
2.陆军军医大学(第三军医大学)军事预防医学系军队流行病学教研室,重庆
3.陆军军医大学(第三军医大学)第一附属医院心内科,重庆
4.重庆医科大学附属第三医院心血管疾病中心,重庆
杨敬源,Email:yangjingyuan@gmc.edu.cn
李亚斐,Email:liyafei2008@hotmail.com
收稿日期:2024-09-16,
修回日期:2025-02-12,
纸质出版日期:2025-03-30
移动端阅览
杨蕾,邬娜,杨岚清,等.外周血piR-hsa-2700592在房颤患者预后中的预测研究[J].陆军军医大学学报,2025,47(06):551-560.DOI:10.16016/j.2097-0927.202409107.
YANG L,WU N,YANG L Q,et al.Predictive value of peripheral blood piR-hsa-2700592 for prognosis of atrial fibrillation patients[J].J Army Med Univ,2025,47(06):551-560.DOI:10.16016/j.2097-0927.202409107.
杨蕾,邬娜,杨岚清,等.外周血piR-hsa-2700592在房颤患者预后中的预测研究[J].陆军军医大学学报,2025,47(06):551-560.DOI:10.16016/j.2097-0927.202409107. DOI:
YANG L,WU N,YANG L Q,et al.Predictive value of peripheral blood piR-hsa-2700592 for prognosis of atrial fibrillation patients[J].J Army Med Univ,2025,47(06):551-560.DOI:10.16016/j.2097-0927.202409107. DOI:
目的
2
探究外周血piR-hsa-2700592与房颤患者全因死亡和卒中结局的关联,确定piR-hsa-2700592是否具有作为房颤生物标志物的潜力。
方法
2
纳入127名非瓣膜性房颤患者,检测血浆piR-hsa-2700592相对表达水平,运用Cox比例风险回归分析外周血piR-hsa-2700592的相对表达水平与房颤患者全因死亡和卒中结局的关联。比较分析在CHA
2
DS
2
-VASc评分及ABC卒中(或死亡)评分中分别加入血浆piR-hsa-2700592表达水平后,其新预测模型对2种结局预测能力的改善情况。应用受试者工作特征曲线下面积(area under the curve,AUC)、净重新分类指数(net reclassification improvement,NRI)、综合判别改善指数(integrated discrimination improvement,IDI)评估预测能力,通过决策曲线分析(decision curve analysis,DCA)比较临床净收益情况。
结果
2
多因素Cox回归分析显示,外周血piR-hsa-2700592高表达水平的患者发生卒中的风险更高(
HR
:2.203;95%
CI
:1.120
~
4.332;
P
=0.022)。在卒中结局中,将血浆piR-hsa-2700592表达水平分别纳入CHA
2
DS
2
-VASc评分及ABC卒中评分相较原评分AUC有显著增加,其新模型AUC分别为0.70(95%
CI
:0.55
~
0.85,
P
<
0.001)和0.84(95%
CI
:0.73
~
0.96,
P
=0.02);高血浆piR-hsa-2700592水平与房颤患者全因死亡无显著关联(HR:1.997;95%
CI
:0.884
~
4.509;
P
=0.096)。新模型的重分类能力得到显著改善,与CHA
2
DS
2
-VASc评分相比其NRI和IDI分别为44.20%(95%
CI
:3.40
~
59.90,
P
<
0.001)和8.20%(95%
CI
:0.60
~
15.40,
P
<
0.001);与ABC卒中评分相比,NRI和IDI分别为44.20%(95%
CI
:9.80
~
58.90,
P
<
0.001)和10.40%(95%
CI
:0.70
~
21.40,
P
<
0.001);DCA曲线显示其新预测模型均有更好的净临床获益。
结论
2
外周血高表达的piR-hsa-2700592是房颤患者发生卒中的独立危险因素,并且对房颤患者的预后有较好的预测价值,提示piR-hsa-2700592可作为潜在生物标志物,为其在心血管疾病诊断和防治中的应用提供依据。
Objectives To explore the association of peripheral blood PIWI-interacting RNA
piR-hsa-2700592
with all-cause mortality and stroke outcomes in patients with atrial fibrillation (AF)
and to determine whether piR-hsa-2700592 has the potential to be an AF biomarker. Methods A total of 127 patients with non-valvular AF were enrolled
and the relative expression level of plasma piR-hsa-2700592 was detected. Cox proportional hazard regression was used to analyze the correlation between the expression of piR-hsa-2700592 and all-cause death as well as stroke outcome in the patients. Then the molecule expression level was combined with CHA
2
DS
2
-VASc score and ABC stroke (or death ) score to establish 2 new prediction models
the improvement of the predictive performance was compared and analyzed. Receiver operating characteristic (ROC) curve analysis (area under the curve
AUC)
net reclassification index (NRI)
and comprehensive discriminant improvement index (IDI) were used to evaluate the predictive performance
and decision curve analysis (DCA) was employed to assess the clinical benefit. Results Multivariate Cox regression analysis showed that the patients with higher expression level of piR-hsa-2700592 in peripheral blood had a higher risk of stroke (
HR
: 2.203
95%CI: 1.120~4.332;
P
=0.022). In the stroke outcome
combination of plasma piR-hsa-2700592 expression level with CHA
2
DS
2
-VASc score and ABC stroke score obtained an AUC of 0.70 (95%
CI
: 0.55~0.85
P
<
0.001) and 0.84 (95%
CI
: 0.73~0.96
P
=0.02)
respectively. But
no significant association was observed between high plasma piR-hsa-2700592 level and all-cause mortality in the AF patients (
HR
: 1.997; 95%
CI
: 0.884~4.509;
P
=0.096). Combination of plasma piR-hsa-2700592 level improved the d
iscriminative capability than the single CHA
2
DS
2
-VASc score and ABC stroke score models
with an NRI and IDI value of 44.20% (95%
CI
: 3.40~59.90
P
<
0.001) and 8.20% (95%
CI
: 0.60~15.40
P
<
0.001)
respectively for the new CHA
2
DS
2
-VASc score model
and an NRI and IDI value of 44.20% (95%
CI
: 9.80~58.90
P
<
0.001) and 10.40% (95%
CI
: 0.70~21.40
P
<
0.001)
respectively for the new ABC stroke score model. The DCA curve showed that both new prediction models obtained better net clinical benefits. Conclusion High peripheral blood expression of piR-hsa-2700592 is an independent risk factor for stroke in the AF patients
and the indicator has a good predictive value for prognosis of the patients. piR-hsa-2700592 might be used as a potential biomarker in the diagnosis and prevention of cardiovascular diseases.
YANG S Y , HUANG M , WANG A L , et al . Atrial fibrillation burden and the risk of stroke: a systematic review and dose-response meta-analysis [J]. World J Clin Cases , 2022 , 10 ( 3 ): 939 - 953 . DOI: 10.12998/wjcc.v10.i3.939 http://dx.doi.org/10.12998/wjcc.v10.i3.939 .
BOTTO G L , TORTORA G , CASALE M C , et al . Impact of the pattern of atrial fibrillation on stroke risk and mortality [J]. Arrhythm Electrophysiol Rev , 2021 , 10 ( 2 ): 68 - 76 . DOI: 10.15420/aer.2021.01 http://dx.doi.org/10.15420/aer.2021.01 .
LIP G Y H , NIEUWLAAT R , PISTERS R , et al . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation [J]. Chest , 2010 , 137 ( 2 ): 263 - 272 . DOI: 10.1378/chest.09-1584 http://dx.doi.org/10.1378/chest.09-1584 .
WU Y X , WANG G Y , DONG L S , et al . Assessment of the CHA 2 DS 2 -VASc score for the prediction of death in elderly patients with coronary artery disease and atrial fibrillation [J]. Front Cardiovasc Med , 2021 , 8 : 805234 . DOI: 10.3389/fcvm.2021.805234 http://dx.doi.org/10.3389/fcvm.2021.805234 .
LIP G Y H , LANE D A . Stroke prevention in atrial fibrillation: a systematic review [J]. JAMA , 2015 , 313 ( 19 ): 1950 - 1962 . DOI: 10.1001/jama.2015.4369 http://dx.doi.org/10.1001/jama.2015.4369 .
HIJAZI Z , LINDBÄCK J , ALEXANDER J H , et al . The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation [J]. Eur Heart J , 2016 , 37 ( 20 ): 1582 - 1590 . DOI: 10.1093/eurheartj/ehw054 http://dx.doi.org/10.1093/eurheartj/ehw054 .
HIJAZI Z , OLDGREN J , LINDBÄCK J , et al . A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score [J]. Eur Heart J , 2018 , 39 ( 6 ): 477 - 485 . DOI: 10.1093/eurheartj/ehx584 http://dx.doi.org/10.1093/eurheartj/ehx584 .
MUSHTAQ I , ISHTIAQ A , ALI T , et al . An overview of non-coding RNAs and cardiovascular system [J]. Adv Exp Med Biol , 2020 , 1229 : 3 - 45 . DOI: 10.1007/978-981-15-1671-9_1 http://dx.doi.org/10.1007/978-981-15-1671-9_1 .
ZHOU Y L , FANG Y , DAI C L , et al . PiRNA pathway in the cardiovascular system: a novel regulator of cardiac differentiation, repair and regeneration [J]. J Mol Med , 2021 , 99 ( 12 ): 1681 - 1690 . DOI: 10.1007/s00109-021-02132-9 http://dx.doi.org/10.1007/s00109-021-02132-9 .
ZHANG K Y , LI Y F , HUANG Y , et al . PiRNA in cardiovascular disease: focus on cardiac remodeling and cardiac protection [J]. J Cardiovasc Transl Res , 2023 , 16 ( 4 ): 768 - 777 . DOI: 10.1007/s12265-023-10353-1 http://dx.doi.org/10.1007/s12265-023-10353-1 .
LI B , WANG K , CHENG W , et al . Recent advances of PIWI-interacting RNA in cardiovascular diseases [J]. Clin Transl Med , 2024 , 14 ( 8 ): e1770 . DOI: 10.1002/ctm2.1770 http://dx.doi.org/10.1002/ctm2.1770 .
ASSOCIATION E H R , SURGERY E A F C , JOHN CAMM A , et al . Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC) [J]. Eur Heart J , 2010 , 31 ( 19 ): 2369 - 2429 . DOI: 10.1093/eurheartj/ehq278 http://dx.doi.org/10.1093/eurheartj/ehq278 .
CAMP R L , DOLLED-FILHART M , RIMM D L . X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization [J]. Clin Cancer Res , 2004 , 10 ( 21 ): 7252 - 7259 . DOI: 10.1158/1078-0432.CCR-04-0713 http://dx.doi.org/10.1158/1078-0432.CCR-04-0713 .
VICKERS A J , CRONIN A M , ELKIN E B , et al . Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers [J]. BMC Med Inform Decis Mak , 2008 , 8 : 53 . DOI: 10.1186/1472-6947-8-53 http://dx.doi.org/10.1186/1472-6947-8-53 .
KURIAKOSE D , XIAO Z C . Pathophysiology and treatment of stroke: present status and future perspectives [J]. Int J Mol Sci , 2020 , 21 ( 20 ): 7609 . DOI: 10.3390/ijms21207609 http://dx.doi.org/10.3390/ijms21207609 .
GAGE B F , WATERMAN A D , SHANNON W , et al . Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation [J]. JAMA , 2001 , 285 ( 22 ): 2864 - 2870 . DOI: 10.1001/jama.285.22.2864 http://dx.doi.org/10.1001/jama.285.22.2864 .
PISTERS R , LANE D A , NIEUWLAAT R , et al . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey [J]. Chest , 2010 , 138 ( 5 ): 1093 - 1100 . DOI: 10.1378/chest.10-0134 http://dx.doi.org/10.1378/chest.10-0134 .
FLEET H , PILCHER D , BELLOMO R , et al . Predicting atrial fibrillation after cardiac surgery: a scoping review of associated factors and systematic review of existing prediction models [J]. Perfusion , 2023 , 38 ( 1 ): 92 - 108 . DOI: 10.1177/02676591211037025 http://dx.doi.org/10.1177/02676591211037025 .
YOSHIMURA H , PROVIDENCIA R , et al . Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion? [J]. Europace , 2024 , 26 ( 11 ): euae280 . DOI: 10.1093/europace/euae280 http://dx.doi.org/10.1093/europace/euae280 .
ALZAABI M A , ABDELSALAM A , ALHAMMADI M , et al . Evaluating biomarkers as tools for early detection and prognosis of heart failure: a comprehensive review [J]. Card Fail Rev , 2024 , 10 : e06 . DOI: 10.15420/cfr.2023.24 http://dx.doi.org/10.15420/cfr.2023.24 .
WANG X , RAMAT A , SIMONELIG M , et al . Emerging roles and functional mechanisms of PIWI-interacting RNAs [J]. Nat Rev Mol Cell Biol , 2023 , 24 ( 2 ): 123 - 141 . DOI: 10.1038/s41580-022-00528-0 http://dx.doi.org/10.1038/s41580-022-00528-0 .
BAI X F , NIU R Z , LIU J , et al . Roles of noncoding RNAs in the initiation and progression of myocardial ischemia-reperfusion injury [J]. Epigenomics , 2021 , 13 ( 9 ): 715 - 743 . DOI: 10.2217/epi-2020-0359 http://dx.doi.org/10.2217/epi-2020-0359 .
GAO X Q , ZHANG Y H , LIU F , et al . The PiRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N 6 -methyladenosine methylation of Parp10 mRNA [J]. Nat Cell Biol , 2020 , 22 ( 11 ): 1319 - 1331 . DOI: 10.1038/s41556-020-0576-y http://dx.doi.org/10.1038/s41556-020-0576-y .
WANG K , ZHOU L Y , LIU F , et al . PIWI-Interacting RNA haapir regulates cardiomyocyte death after myocardial infarction by promoting NAT10-Mediated ac 4 C acetylation of tfec mRNA [J]. Adv Sci , 2022 , 9 ( 8 ): e2106058 . DOI: 10.1002/advs.202106058 http://dx.doi.org/10.1002/advs.202106058 .
SHANMUGHA RAJAN K , VELMURUGAN G , GOPAL P , et al . Abundant and altered expression of PIWI-interacting RNAs during cardiac hypertrophy [J]. Heart Lung Circ , 2016 , 25 ( 10 ): 1013 - 1020 . DOI: 10.1016/j.hlc.2016. 02.015 http://dx.doi.org/10.1016/j.hlc.2016.02.015 .
LIPPS C , NORTHE P , FIGUEIREDO R , et al . Non-invasive approach for evaluation of pulmonary hypertension using extracellular vesicle-associated small non-coding RNA [J]. Biomolecules , 2019 , 9 ( 11 ): 666 . DOI: 10.3390/biom9110666 http://dx.doi.org/10.3390/biom9110666 .
YANG J , XUE F T , LI Y Y , et al . Exosomal PiRNA sequencing reveals differences between heart failure and healthy patients [J]. Eur Rev Med Pharmacol Sci , 2018 , 22 ( 22 ): 7952 - 7961 . DOI: 10.26355/eurrev_201811_16423 http://dx.doi.org/10.26355/eurrev_201811_16423 .
MA C , ZHANG L X , WANG X Y , et al . piRNA-63076 contributes to pulmonary arterial smooth muscle cell proliferation through acyl-CoA dehydrogenase [J]. J Cell Mol Med , 2020 , 24 ( 9 ): 5260 - 5273 . DOI: 10.1111/jcmm.15179 http://dx.doi.org/10.1111/jcmm.15179 .
SAMAN H , RAZA A , PATIL K , et al . Non-invasive biomarkers for early lung cancer detection [J]. Cancers , 2022 , 14 ( 23 ): 5782 . DOI: 10.3390/cancers14235782 http://dx.doi.org/10.3390/cancers14235782 .
KATKI H A . Quantifying risk stratification provided by diagnostic tests and risk predictions: comparison to AUC and decision curve analysis [J]. Stat Med , 2019 , 38 ( 16 ): 2943 - 2955 . DOI: 10.1002/sim.8163 http://dx.doi.org/10.1002/sim.8163 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621